
May 28 (Reuters) - Rezolute Inc RZLT.O:
REZOLUTE ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 3 SUNRIZE STUDY OF ERSODETUG IN PATIENTS WITH CONGENITAL HYPERINSULINISM
REZOLUTE INC - TOPLINE DATA ANTICIPATED IN DECEMBER 2025
REZOLUTE INC - ANTICIPATES BLA SUBMISSION FOR ERSODETUG IN 2026